Boston, MA
Summary
This biotechnology company focuses on curing blood cancers through innovative cell and genome engineering techniques. Their unique approach involves developing shielded transplants that allow for the delivery of potentially curative treatments after a stem cell transplant, specifically targeting acute myeloid leukemia (AML) and other blood cancers. The company utilizes a proprietary platform that integrates Hematopoietic Stem Cell (HSC) biology, genome engineering, and CAR-T cell technology to enhance treatment efficacy and reduce relapse rates.
Subdomain
Target
vorbio.gcs-web.com
vorbiopharma.samanage.com
107.170.196.140 -